List of Biochemicals Stocks
Biochemicals stocks are publicly traded companies whose business involves using plant or animal based feedstocks (biomass) to create new chemicals or substitutes of existing petrochemicals, plastics, or other fossil fuel derived substances other than fuels.
Amyris (AMRS)
BioAmber (BIOA)
Bion Environmental Technologies (BNET)
Codexis (CDXS)
Corbion (CRBN.AS; CSNVY)
Eastman Chemical Company (EMN)
Global Bioenergies (ALGBE: EURONEXT)
Novozymes (Copenhagen:NZYM-B; OTC:NVZMY)
Royal DSM (DSM.AS; KDSKF; RDSMY)
SECOS Group (SES.AX)
If you know of any biochemicals stock that is not listed here and should be, please let us know by leaving a comment. Also for stocks in the list that you think should be removed.
Two Thumbs Up for Solazyme: AkzoNobel deal, new technology for structured oils
Jim Lane The sector’s perennial hottest company strikes again with “potentially disruptive” new technology to change the positioning and performance of triglyceride oils. In California, Solazyme (SZYM) and AkzoNobel announced an agreement targeting the development of advanced tailored triglyceride oils and commercial sales for near-term product supply. The agreement focuses on supply for the chemical giant’s Surface Chemistry and Decorative Paints businesses. Commercial supply of multi-thousand ton quantities of highly sustainable algal oil is expected to originate from the Solazyme Bunge Renewable Oils Joint Venture oil manufacturing plant in Brazil. Sales of product are anticipated to commence...
Bion: Waste To Dollars
Earlier this week Bion Environmental Technologies (BNET) received approval of a patent for its proprietary ammonia recovery process. Bion’s technology converts livestock wastes into ammonium bicarbonate. Patent protection in the U.S. paves the way for Bion to deliver an environmentally friendly chemical to the market at attractive profit margins.
Ammonium bicarbonate is used for a variety of purposes from leavening to crop additives. It is the fertilizer market that has caught Bion’s attention. The company intends to ‘close the loop’ for the agricultural sector by helping livestock producers economically dispose of waste and then delivering a fertilizer for food crops that qualifies as organic.
It is an attractive...
Biofuels & Biobased Earnings Roundup: Amyris
by Jim Lane
The Top Line. In California, Amyris (AMRS) reported Q2 GAAP revenue for the second quarter of 2018 of $24.8 million, compared with $25.7 million for the second quarter of 2017. Grants and collaborations revenue was $11.4 million for the second quarter of 2018 compared with $10.3 million for the year-ago period. The company noted that Q2 revenue was $24.8 million compared with the same period in 2017 of $21.7 million when adjusted for the low margin product sales on contracts assigned to DSM (DSM.AS). This reflects 15% growth on an absolute basis. GAAP net loss for the first half was $89.1...
Amyris’ Missing Magic
by Debra Fiakas CFA Since the end of August last year shares of renewable chemicals developer Amyris (AMRS: Nasdaq) have been in a steady decline. Since falling through a line of price support near the $2.50 price level in early December 2014, it appears there is no safety net for AMRS. The stock set a new 52-week low in the third week in January 2015. Unfortunately, a popular technical indicator, the average directional index, is providing a very strong indication that the stock could fall even further. With its stock chart providing no hints at a reversal in...
BioAmber’s $150 Million IPO: The 10-Minute Version
Jim Lane A first-to-market leader in bio-succinic acid comes to the public markets with its IPO. Can BioAmber translate a lead in succinic acid’s smallish market into leadership in a vast array of high-priced renewable chemicals? Here’s our 10-minute version of the BioAmber IPO, with a translation of the risks into English. In Minnesota, BioAmber has filed an S-1 registration statement for a proposed $150 million initial public offering. The number of shares to be offered in the proposed offering and the price range for the offering have not yet been determined. The lead book-running managers for...
Amber Means Caution But BioAmber Means Go
Jim Lane In Canada, BioAmber (BIOA) recorded net income of $4.8M for Q2 2016 and an operating loss of $1.0M on revenues of $2.5M. Revenues were up 73 percent over Q1 and 637 percent compared to Q2 2015. For those less familiar with the company, it produces succinic acid from sugar at a first commercial-scale plant which opened recently in Sarnia, Ontario. Succinic acid has a small existing global market but can be converted into a variety of chemical building blocks used to produce a range of plastics, paints, textiles, food additives and personal care products. If for...
The Hocky-Stick Growth of Biobased Intermediates
Super-cali-thali-terpa-butyl-peta what? Jim Lane The new trend in biofuels is not a biofuel at all – it’s an (usually unpronounceable) intermediate that can be refined into an array of fuels, chemicals, flavors, fragrances, and construction or packaging materials. Ptera-buta-thalic-what? We can hardly pronounce them, but we sure need to know about them. Amyris (AMRS), KiOR (KIOR), Renmatix, Virdia, Blue Sugars, Proterro, Sucre Source, Sweetwater Energy, Genomatica – hot companies all, what do they have in common? Instead of making a finished end-product, they make an intermediate which is then upgraded to a finished product, typically...
Avantium IPO “Many Times Oversubscribed:” What Buyers Are So Excited About
Jim Lane In France, Avantium completed its highly-anticipated initial public offering, raising $109.5M (€103M) via the sale of 9,401,793 shares at $11.70 (€11) per share, giving the company a market capitalization reaches of $294M (€277M). Trading will begin on March 15th 2017 on Euronext Amsterdam and Euronext Bruxelles under the symbol AVTX. The Company anticipates to use €65-75 million of the net proceeds of the Offering for the funding of the Joint Venture, enabling it to construct and operate the reference plant for the commercialization of the YXY technology. The company’s first world-scale plant is a 50,000 tons...
Ramp-Up Delay Sends Solazyme Stock Into Free-Fall
Jim Lane Revenue and customer numbers are up at Solazyme (SZYM), 60% YOY growth from Q3 2013 to Q3 2014. But a slowdown in the rollout at Moema capacity leads to a spectacular 58% one-day drop in the stock price. What happened? Solazyme has been on a relatively steady downward trajectory for the past few quarters, dropping from the $11-$13 range and down into the $6-$8 range. And then plunged a stunning 58 percent to $3.14 yesterday – amidst downgrades by Cowen & Company, Pacific Crest and Baird generally to Market Perform or Neutral, and remains...
Lower Revenues at Solazyme, But Also Lower Losses and New Customers
Jim Lane In California, Solazyme (SZYM) reported Q2 revenues of $11.7M compared with $15.9M in Q22014. GAAP net loss was $37.2 million for Q2 2015, compared to net loss of $42.9M in the prior year period. The company said that “year over year decline in revenues was due to expected decreases in funded program revenue as well as in product revenue due to the timing of certain Algenist sales activities and slower than anticipated adoption rates for Encapso.” The market responded to the results by slashing the stock price 20 percent in Friday trading. Analyst reaction was more positive,...
Gevo Begins To Ship Missing Link For 100% Renewable Plastic Bottles
Jim Lane From Colorado, news has arrived that Gevo (GEVO) is now selling paraxyleme to Toray (TRYIF), one of the world’s leading producers of fibers, plastics, films, and chemicals. It’s producing PX from isobutanol, one of its three molecules in production (the others are jet fuel and iso-ocrane) at its complex in Silsbee, Texas. Toray expects to produce fibers, yarns, and films from Gevo’s PX. While any new molecule attached to a major customer relationship is always big news for any producer this has special significance. Let’s review exactly why....
Solazyme’s Detours on the Way to Algae Biofuel
by Debra Fiakas CFA Investors who took the time to read my last two posts on algae-based biofuel – “Algae Takes Flight” and “Emission Standards Driving Aviation Fuel Sourcing” - might have wondered why there was no mention of Solazyme, Inc. (SZYM: Nasdaq). California-based Solazyme has been pursuing algae-based oils for transportation since 2004, and managed to record its first product sales in 2011. However, that revenue was not from biofuel. On the long road to finding a scalable and efficient way to get renewable fuel from algae, Solazyme scientists found an interesting extract...
Biofuels & Biobased Earnings Roundup: DSM
by Jim Lane
The Top Line. In the Netherlands, Royal DSM (Amsterdam: DSM.AS; US OTC:KDSKF; US ADR:RDSMY) reported a good H1 with organic sales growth in underlying business estimated at 10% and adjusted EBITDA growth of underlying business estimated at 7%, with sales of €4,794 million and adjusted EBITDA of €771 million.
The Big Highlights. Nutrition: an estimated 8% underlying organic sales growth and Adjusted EBITDA growth of underlying business estimated at 6%. Materials: 7% organic sales growth and Adjusted EBITDA growth of 5%. DSM also confirmed its full year outlook 2018, as provided at Q1 2018, and expects an Adjusted EBITDA growth towards...
Novozymes Ignites Yeast Wars
Novozymes (Copenhagen:NZYM-B; OTC:NVZMY) moved into yeast this week with a new organism, Innova Drive.
It’s saccharomyces cerevisae — the workhouse yeast that has been powering wine fermentation since the days of Noah and the Ark. But here’s a new strain engineered to cut fermentation times up to two hours, and yield boosts of up to two percent.
A 2% yield increase and a 5% faster rate of production — let’s illustrate it — would mean something like 7.1 million gallons per year of more ethanol from the same standard 100 million gallon nameplate plant. Retailing at up to $10 million dollars, per year (yes,...
More Gevolution
Jim Lane The results from Gevo’s (GEVO) 4th quarter are in, and a worth a look-see, not only for fans of isobutanol and its prospects. Also for a look at how this member of the 2010-12 IPO group of companies is crossing the multiple Valleys of Death that have arrayed before it. In the fourth quarter of 2014, Gevo continued to progress the commercial operation of isobutanol at Luverne under the Side-by-Side mode of production (SBS), meeting its stated milestone in December 2014 of producing greater than 50K gallons of isobutanol in one month. This achievement, Gevo notes,...